circVec (Cancer Gene Therapy)
Cancer
Discovery/In vivo PoCActive
Key Facts
About Circio
Circio is a public biotechnology company pioneering the development of circular RNA therapeutics. Its core asset is the circVec platform, a modular genetic cassette system designed to produce multifunctional circRNA inside cells, demonstrating significantly enhanced and more durable protein expression compared to conventional mRNA. While advancing its circRNA platform for applications in gene therapy, vaccines, and rare diseases, the company is also progressing its clinical-stage cancer vaccine, TG01, through external collaborations. Circio aims to establish circVec as a new gold-standard platform for nucleic acid and viral therapeutics.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |